Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Otesaconazole - Mycovia Pharmaceuticals

Drug Profile

Otesaconazole - Mycovia Pharmaceuticals

Alternative Names: VT-1161

Latest Information Update: 23 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Viamet Pharmaceuticals
  • Developer Mycovia Pharmaceuticals; Viamet Pharmaceuticals
  • Class Antifungals; Pyridines; Small molecules; Tetrazoles
  • Mechanism of Action 14-alpha demethylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Vulvovaginal candidiasis
  • Phase II Onychomycosis
  • No development reported Tinea pedis

Most Recent Events

  • 13 Nov 2019 Mycovia Pharmaceuticals completes enrolment in the first phase III VIOLET trial for Vulvovaginal candidiasis (In children, In adolescents, In adults, Recurrent) in USA, Japan, Bulgaria, Poland and United Kingdom (PO) (NCT03562156 ) (EudraCT2018-001269-18)
  • 13 Nov 2019 Mycovia Pharmaceuticals completes enrolment in the second phase III VIOLET trial for Vulvovaginal candidiasis (In children, In adolescents, In adults, Recurrent) in USA, Japan, Czech Republic, Belgium and Hungary (PO) (NCT03561701) (EudraCT2018-001270-26)
  • 16 Oct 2019 Mycovia Pharmaceuticals and Gedeon Richter entered into development and marketing agreement to manufacture and commercialise otesaconazole in Europe, Australia, Latin America, Russia and CIS countries for the treatment of Vulvovaginal candidiasis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top